- Home
- MNMD vs ORC Comparison
MNMD vs ORC Comparison
Compare MNMD & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- ORC
- Stock Information
- Founded
- MNMD 2019
- ORC 2010
- Country
- MNMD United States
- ORC United States
- Employees
- MNMD N/A
- ORC N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- ORC Real Estate Investment Trusts
- Sector
- MNMD Health Care
- ORC Real Estate
- Exchange
- MNMD Nasdaq
- ORC Nasdaq
- Market Cap
- MNMD 960.2M
- ORC 1.0B
- IPO Year
- MNMD N/A
- ORC 2013
- Fundamental
- Price
- MNMD $11.01
- ORC $7.37
- Analyst Decision
- MNMD Strong Buy
- ORC Hold
- Analyst Count
- MNMD 7
- ORC 2
- Target Price
- MNMD $26.71
- ORC N/A
- AVG Volume (30 Days)
- MNMD 2.3M
- ORC 6.0M
- Earning Date
- MNMD 11-06-2025
- ORC 10-23-2025
- Dividend Yield
- MNMD N/A
- ORC 19.67%
- EPS Growth
- MNMD N/A
- ORC N/A
- EPS
- MNMD N/A
- ORC 0.57
- Revenue
- MNMD N/A
- ORC $80,187,000.00
- Revenue This Year
- MNMD N/A
- ORC $75.23
- Revenue Next Year
- MNMD N/A
- ORC $53.72
- P/E Ratio
- MNMD N/A
- ORC $12.76
- Revenue Growth
- MNMD N/A
- ORC 5.93
- 52 Week Low
- MNMD $4.70
- ORC $5.69
- 52 Week High
- MNMD $14.43
- ORC $9.01
- Technical
- Relative Strength Index (RSI)
- MNMD 41.39
- ORC 52.32
- Support Level
- MNMD $12.60
- ORC $7.12
- Resistance Level
- MNMD $14.43
- ORC $7.43
- Average True Range (ATR)
- MNMD 0.84
- ORC 0.15
- MACD
- MNMD -0.30
- ORC -0.02
- Stochastic Oscillator
- MNMD 11.52
- ORC 37.12
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.